Skip to content
Accueil Quality

Maintenance & updating

Maintenance and updating of the information contained in the Orthodose application.

Executive Summary

Orthodose developed MedLight srl by represents a significant advance in medical applications dedicated to palliative care and pain management. Initially created in 2010 by a doctor specializing in palliative care, it offers healthcare professionals useful, accurate and actionable information on palliative care pain management and relevant conversion calculations. Orthodose stands as an indispensable tool for improving palliative care quality worldwide.

In a landscape awash with varying information, Orthodose stands out by providing information fuelled by Evidence Based Medicine, yet practical, peer-used practical information, facilitating enlightened therapeutic decisions. It is important to emphasize that Orthodose provides theoretical information for professional use, devoid of patient-specific diagnostics or treatment options, underscoring the necessity for healthcare professionals to tailor application advice to individual patient contexts.

Procedure to Ensure Up-to-Date and Accurate Medical App Information

In order to constantly maintain the accuracy and relevance of Orthodose, we have developed a specific procedure to ensure that the medical information in the application remains up-to-date and accurate. This history underscores the application’s enduring commitment to quality, security, and patient safety, making it a trusted resource in the palliative care community.

Content Review Cycle

A rigorous content review cycle involves clinical expert in palliative care and explicitly includes supervision by a medical doctor. It ensures that updates and assessments of the app’s medical content are overseen by a qualified healthcare professional, reinforcing the app’s credibility and reliability. This cycle is designed to incorporate the latest clinical guidelines, research findings, and evidence-based practices, with updates occurring annually or more frequently as needed. This cycle explicitly acknowledges the balance between the application’s practicality and the necessity for it to remain secure and up to date, ensuring that decisions to update are informed not only by the latest articles but also by their applicability and safety in clinical use.

User Feedback Integration

The mechanism for integrating user feedback, collected through the app and website, is detailed further to emphasize its effectiveness. This process, conducted monthly, involves reviewing feedback to identify scientific references and prioritize updates, reinforcing the app’s responsiveness to user needs and enhancing its practical utility. The inclusion of user feedback in the literature review process, and the decision not to list all sources in the bibliography due to the long-standing nature of this review (commencing 15 years ago), are new additions. This approach ensures a relatively concise yet comprehensive bibliography.

Literature and Guidelines Monitoring

The ongoing monitoring of scientific literature, clinical guidelines, and regulatory updates is crucial. This process involves continuous scanning of new information relevant to pain management in palliative care, ensuring that the app remains a current and practical resource for healthcare professionals. This monitoring explicitly includes the criteria of quality, practicality and security in the evaluation of new information for app integration, ensuring that updates not only reflect the latest scientific findings but are also viable and safe for clinical application.

Quality Assurance and Validation

The quality assurance and validation section has been expanded to detail the testing process by “testers”, including medical doctors, ensuring that updates do not compromise the app’s functionality or reliability. Users interested in participating as testers are encouraged to apply through the Orthodose contact page, fostering a community-driven approach to app development and quality assurance.

Change Log and Version Control

With the detailed background of Orthodose’s creation and MEDLIGHT SRL’s stewardship, the application has undergone significant enhancements to solidify its position as a reliable, effective, and compliant tool for palliative care professionals. MEDLIGHT’s approach, incorporating rigorous update cycles, user feedback integration, continuous monitoring of scientific literature, and comprehensive quality assurance, builds a robust foundation for trust among users. This commitment to excellence and patient safety is now further emphasized in our change log version notes, reflecting our dedication to maintaining Orthodose as a premier resource for healthcare professionals. By incorporating these detailed procedures, MEDLIGHT SRL ensures that Orthodose continues to be a dependable and efficient tool for target information, fostering greater trust and demonstrating a steadfast commitment to quality and patient safety in palliative care.

Bibliography

The bibliography will be selectively compiled to reflect the extensive literature review spanning over 15 years, emphasizing key references that inform the app’s content, such as:

  1. Cherny, Nathan I., and others (eds), Oxford Textbook of Palliative Medicine, 6 edn (Oxford, 2021; online edn, Oxford Academic, 1 Aug. 2021), https://doi.org/10.1093/med/9780198821328.001.0001, accessed 1 Apr. 2024.

  2. Caraceni, A., Hanks, G., Kaasa, S., Bennett, M. I., Brunelli, C., Cherny, N., Dale, O., De Conno, F., Fallon, M., Hanna, M., Haugen, D. F., Juhl, G., King, S., Klepstad, P., Laugsand, E. A., Maltoni, M., Mercadante, S., Nabal, M., Pigni, A., Radbruch, L., … European Association for Palliative Care (EAPC) (2012). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. The Lancet. Oncology, 13(2), e58–e68. https://doi.org/10.1016/S1470-2045(12)70040-2

  3. Nelson, K. A., Glare, P. A., Walsh, D., & Groh, E. S. (1997). A prospective, within-patient, crossover study of continuous intravenous and subcutaneous morphine for chronic cancer pain. Journal of pain and symptom management, 13(5), 262–267. https://doi.org/10.1016/s0885-3924(96)00329-6

  4. Cole, S. G., Brozinsky, S., & Isenberg, J. I. (1983). Midazolam, a new more potent benzodiazepine, compared with diazepam: a randomized, double-blind study of preendoscopic sedatives. Gastrointestinal endoscopy, 29(3), 219–222. https://doi.org/10.1016/s0016-5107(83)72588-5

  5. Schuster, M., Bayer, O., Heid, F., & Laufenberg-Feldmann, R. (2018). Opioid Rotation in Cancer Pain Treatment. Deutsches Arzteblatt international, 115(9), 135–142. https://doi.org/10.3238/arztebl.2018.0135

  6. Alford, D. P., Compton, P., & Samet, J. H. (2006). Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Annals of internal medicine, 144(2), 127–134. https://doi.org/10.7326/0003-4819-144-2-200601170-00010

  7. McKenzie, C. A., McKinnon, W., Naughton, D. P., Treacher, D., Davies, G., Phillips, G. J., & Hilton, P. J. (2005). Differentiating midazolam over-sedation from neurological damage in the intensive care unit. Critical care (London, England), 9(1), R32–R36. https://doi.org/10.1186/cc3010

  8. Lugo, R. A., Satterfield, K. L., & Kern, S. E. (2005). Pharmacokinetics of methadone. Journal of pain & palliative care pharmacotherapy, 19(4), 13–24.

  9. Sittl, R., Nuijten, M., & Poulsen Nautrup, B. (2006). Patterns of dosage changes with transdermal buprenorphine and transdermal fentanyl for the treatment of noncancer and cancer pain: a retrospective data analysis in Germany. Clinical therapeutics, 28(8), 1144–1154. https://doi.org/10.1016/j.clinthera.2006.08.002

  10. Derendorf, H., Möllmann, H., Barth, J., Möllmann, C., Tunn, S., & Krieg, M. (1991). Pharmacokinetics and oral bioavailability of hydrocortisone. Journal of clinical pharmacology, 31(5), 473–476. https://doi.org/10.1002/j.1552-4604.1991.tb01906.x

  11. Heazelwood, V. J., Galligan, J. P., Cannell, G. R., Bochner, F., & Mortimer, R. H. (1984). Plasma cortisol delivery from oral cortisol and cortisone acetate: relative bioavailability. British journal of clinical pharmacology, 17(1), 55–59. https://doi.org/10.1111/j.1365-2125.1984.tb04999.x

  12. Spoorenberg, S. M., Deneer, V. H., Grutters, J. C., Pulles, A. E., Voorn, G. P., Rijkers, G. T., Bos, W. J., & van de Garde, E. M. (2014). Pharmacokinetics of oral vs. intravenous dexamethasone in patients hospitalized with community-acquired pneumonia. British journal of clinical pharmacology, 78(1), 78–83. https://doi.org/10.1111/bcp.12295

  13. Pöyhiä, R., Seppälä, T., Olkkola, K. T., & Kalso, E. (1992). The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. British journal of clinical pharmacology, 33(6), 617–621. https://doi.org/10.1111/j.1365-2125.1992.tb04090.x

  14. Navigante, A. H., Cerchietti, L. C., Castro, M. A., Lutteral, M. A., & Cabalar, M. E. (2006). Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of pain and symptom management, 31(1), 38–47. https://doi.org/10.1016/j.jpainsymman.2005.06.009

  15. Sandouk, P., Serrie, A., Scherrmann, J. M., Langlade, A., & Bourre, J. M. (1991). Presence of morphine metabolites in human cerebrospinal fluid after intracerebroventricular administration of morphine. European journal of drug metabolism and pharmacokinetics, Spec No 3, 166–171.

  16. Baker, J., Dickman, A., Mason, S., & Ellershaw, J. (2018). The current evidence base for the feasibility of 48-hour continuous subcutaneous infusions (CSCIs): A systematically-structured review. PloS one, 13(3), e0194236. https://doi.org/10.1371/journal.pone.0194236

  17. Moksnes, K., Dale, O., Rosland, J. H., Paulsen, O., Klepstad, P., & Kaasa, S. (2011). How to switch from morphine or oxycodone to methadone in cancer patients? a randomised clinical phase II trial. European journal of cancer (Oxford, England : 1990), 47(16), 2463–2470. https://doi.org/10.1016/j.ejca.2011.06.047

  18. Klimas, R., & Mikus, G. (2014). Morphine-6-glucuronide is responsible for the analgesic effect after morphine administration: a quantitative review of morphine, morphine-6-glucuronide, and morphine-3-glucuronide. British journal of anaesthesia, 113(6), 935–944. https://doi.org/10.1093/bja/aeu186

  19. Westerling, D., Höglund, P., Lundin, S., & Svedman, P. (1994). Transdermal administration of morphine to healthy subjects. British journal of clinical pharmacology, 37(6), 571–576. https://doi.org/10.1111/j.1365-2125.1994.tb04306.x

  20. Donnelly R. F. (2009). Physical compatibility and chemical stability of ketamine-morphine mixtures in polypropylene syringes. The Canadian journal of hospital pharmacy, 62(1), 28–33. https://doi.org/10.4212/cjhp.v62i1.114

  21. Bloomfield, S. S., Cissell, G. B., Mitchell, J., Barden, T. P., Kaiko, R. F., Fitzmartin, R. D., Grandy, R. P., Komorowski, J., & Goldenheim, P. D. (1993). Analgesic efficacy and potency of two oral controlled-release morphine preparations. Clinical pharmacology and therapeutics, 53(4), 469–478. https://doi.org/10.1038/clpt.1993.53

  22. Edge, W. G., Cooper, G. M., & Morgan, M. (1979). Analgesic effects of sublingual buprenorphine. Anaesthesia, 34(5), 463–467. https://doi.org/10.1111/j.1365-2044.1979.tb06325.x

  23. Morrow, S. A., Stoian, C. A., Dmitrovic, J., Chan, S. C., & Metz, L. M. (2004). The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis. Neurology, 63(6), 1079–1080. https://doi.org/10.1212/01.wnl.0000138572.82125.f5

  24. Bao, Y. J., Hou, W., Kong, X. Y., Yang, L., Xia, J., Hua, B. J., & Knaggs, R. (2016). Hydromorphone for cancer pain. The Cochrane database of systematic reviews, 10(10), CD011108. https://doi.org/10.1002/14651858.CD011108.pub2

  25. Caraceni, A., Hanks, G., Kaasa, S., Bennett, M. I., Brunelli, C., Cherny, N., Dale, O., De Conno, F., Fallon, M., Hanna, M., Haugen, D. F., Juhl, G., King, S., Klepstad, P., Laugsand, E. A., Maltoni, M., Mercadante, S., Nabal, M., Pigni, A., Radbruch, L., … European Association for Palliative Care (EAPC) (2012). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. The Lancet. Oncology, 13(2), e58–e68. https://doi.org/10.1016/S1470-2045(12)70040-2

  26. Ofoegbu, A., & B Ettienne, E. (2021). Pharmacogenomics and Morphine. Journal of clinical pharmacology, 61(9), 1149–1155. https://doi.org/10.1002/jcph.1873

  27. Wittwer, E., & Kern, S. E. (2006). Role of morphine’s metabolites in analgesia: concepts and controversies. The AAPS journal, 8(2), E348–E352. https://doi.org/10.1007/BF02854905

  28. Watanabe, S., Pereira, J., Tarumi, Y., Hanson, J., & Bruera, E. (2008). A randomized double-blind crossover comparison of continuous and intermittent subcutaneous administration of opioid for cancer pain. Journal of palliative medicine, 11(4), 570–574. https://doi.org/10.1089/jpm.2007.0176

  29. De Gregori, S., De Gregori, M., Ranzani, G. N., Allegri, M., Minella, C., & Regazzi, M. (2012). Morphine metabolism, transport and brain disposition. Metabolic brain disease, 27(1), 1–5. https://doi.org/10.1007/s11011-011-9274-6

  30. Takahashi, M., Ohara, T., Yamanaka, H., Shimada, A., Nakaho, T., & Makoto, Y. (2003). The oral-to-intravenous equianalgesic ratio of morphine based on plasma concentrations of morphine and metabolites in advanced cancer patients receiving chronic morphine treatment. Palliative medicine, 17(8), 673–678. https://doi.org/10.1191/0269216303pm824oa

  31. Hagen, N. A., & Babul, N. (1997). Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer, 79(7), 1428–1437.

  32. Lasheen, W., Walsh, D., Mahmoud, F., Sarhill, N., Rivera, N., Davis, M., Lagman, R., & Legrand, S. (2010). The intravenous to oral relative milligram potency ratio of morphine during chronic dosing in cancer pain. Palliative medicine, 24(1), 9–16. https://doi.org/10.1177/0269216309346595

  33. Poulain, P., Berleur, M. P., Lefki, S., Lefebvre, D., Chvetzoff, G., Serra, E., Tremellat, F., Derniaux, A., Filbet, M., & EQUIMETH2 Study Group (2016). Efficacy and Safety of Two Methadone Titration Methods for the Treatment of Cancer-Related Pain: The EQUIMETH2 Trial (Methadone for Cancer-Related Pain). Journal of pain and symptom management, 52(5), 626–636.e1. https://doi.org/10.1016/j.jpainsymman.2016.05.022

  34. Link, B., Haschke, M., Grignaschi, N., Bodmer, M., Aschmann, Y. Z., Wenk, M., & Krähenbühl, S. (2008). Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping. British journal of clinical pharmacology, 66(4), 473–484. https://doi.org/10.1111/j.1365-2125.2008.03201.x

  35. Riss, J., Cloyd, J., Gates, J., & Collins, S. (2008). Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta neurologica Scandinavica, 118(2), 69–86. https://doi.org/10.1111/j.1600-0404.2008.01004.x

  36. Pecking, M., Montestruc, F., Marquet, P., Wodey, E., Homery, M. C., & Dostert, P. (2002). Absolute bioavailability of midazolam after subcutaneous administration to healthy volunteers. British journal of clinical pharmacology, 54(4), 357–362. https://doi.org/10.1046/j.1365-2125.2002.01665.x

  37. Gálvez, R., Schäfer, M., Hans, G., Falke, D., & Steigerwald, I. (2013). Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study. Advances in therapy, 30(3), 229–259. https://doi.org/10.1007/s12325-013-0015-6

  38. Scott, L. J., Lyseng-Williamson, K. A., & Garnock-Jones, K. P. (2012). Oromucosal midazolam: a guide to its use in paediatric patients with prolonged acute convulsive seizures. CNS drugs, 26(10), 893–897. https://doi.org/10.2165/11209350-000000000-00000

  39. Bruera, E., Pereira, J., Watanabe, S., Belzile, M., Kuehn, N., & Hanson, J. (1996). Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer, 78(4), 852–857. https://doi.org/10.1002/(SICI)1097-0142(19960815)78:4<852::AID-CNCR23>3.0.CO;2-T

  40. Spénard, J., Caillé, G., de Montigny, C., Vézina, M., Ouellette, J., Larivière, L., & Trudel, F. (1988). Placebo-controlled comparative study of the anxiolytic activity and of the pharmacokinetics of oral and sublingual lorazepam in generalized anxiety. Biopharmaceutics & drug disposition, 9(5), 457–464. https://doi.org/10.1002/bod.2510090504

  41. Moulin, D. E., Kreeft, J. H., Murray-Parsons, N., & Bouquillon, A. I. (1991). Comparison of continuous subcutaneous and intravenous hydromorphone infusions for management of cancer pain. Lancet (London, England), 337(8739), 465–468. https://doi.org/10.1016/0140-6736(91)93401-t

  42. Whitwam, J. G., Al-Khudhairi, D., & McCloy, R. F. (1983). Comparison of midazolam and diazepam in doses of comparable potency during gastroscopy. British journal of anaesthesia, 55(8), 773–777. https://doi.org/10.1093/bja/55.8.773

  43. Zilker, M., Sörgel, F., & Holzgrabe, U. (2019). A systematic review of the stability of finished pharmaceutical products and drug substances beyond their labeled expiry dates. Journal of pharmaceutical and biomedical analysis, 166, 222–235. https://doi.org/10.1016/j.jpba.2019.01.016

  44. Simpson, R. J., Power, K. G., Wallace, L. A., Butcher, M. H., Swanson, V., & Simpson, E. C. (1990). Controlled comparison of the characteristics of long-term benzodiazepine users in general practice. The British journal of general practice : the journal of the Royal College of General Practitioners, 40(330), 22–26.

  45. Waldmann, C. S., Eason, J. R., Rambohul, E., & Hanson, G. C. (1984). Serum morphine levels. A comparison between continuous subcutaneous infusion and continuous intravenous infusion in postoperative patients. Anaesthesia, 39(8), 768–771. https://doi.org/10.1111/j.1365-2044.1984.tb06520.x

  46. Stuart-Harris, R., Joel, S. P., McDonald, P., Currow, D., & Slevin, M. L. (2000). The pharmacokinetics of morphine and morphine glucuronide metabolites after subcutaneous bolus injection and subcutaneous infusion of morphine. British journal of clinical pharmacology, 49(3), 207–214. https://doi.org/10.1046/j.1365-2125.2000.00141.x

  47. Patel, M., Taskar, K. S., & Zamek-Gliszczynski, M. J. (2016). Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites. Journal of clinical pharmacology, 56 Suppl 7, S23–S39. https://doi.org/10.1002/jcph.671

  48. Kokubun, H., Yoshimoto, T., Hojo, M., Fukumura, K., & Matoba, M. (2014). Pharmacokinetics of oxycodone after intravenous and subcutaneous administration in Japanese patients with cancer pain. Journal of pain & palliative care pharmacotherapy, 28(4), 338–350. https://doi.org/10.3109/15360288.2014.969872

  49. Elkader, A., & Sproule, B. (2005). Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clinical pharmacokinetics, 44(7), 661–680. https://doi.org/10.2165/00003088-200544070-00001

  50. Moulin, D. E., Kreeft, J. H., Murray-Parsons, N., & Bouquillon, A. I. (1991). Comparison of continuous subcutaneous and intravenous hydromorphone infusions for management of cancer pain. Lancet (London, England), 337(8739), 465–468. https://doi.org/10.1016/0140-6736(91)93401-t

  51. Imanaka, K., Tominaga, Y., Etropolski, M., Ohashi, H., Hirose, K., & Matsumura, T. (2014). Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release. Clinical drug investigation, 34(7), 501–511. https://doi.org/10.1007/s40261-014-0204-3

  52. Allwood M. The stability of diamorphine alone and in combination with anti-emetics in plastic syringes. Palliative Medicine. 1991;5(4):330-333. doi:10.1177/026921639100500409

  53. Quigley C. (2004). Opioid switching to improve pain relief and drug tolerability. The Cochrane database of systematic reviews, (3), CD004847. https://doi.org/10.1002/14651858.CD004847

  54. Ni, Y., Gao, H., Ouyang, W., Yang, G., Cheng, M., & Ding, L. (2024). Pharmacokinetics, metabolite profiling, safety and tolerability of YZJ-4729 tartrate, a novel G protein-biased μ-opioid receptor agonist, in healthy Chinese subjects. Frontiers in pharmacology, 14, 1295319. https://doi.org/10.3389/fphar.2023.1295319

  55. Wiffen, P. J., Edwards, J. E., Barden, J., & McQuay, H. J. (2003). Oral morphine for cancer pain. The Cochrane database of systematic reviews, (4), CD003868. https://doi.org/10.1002/14651858.CD003868

  56. King, S., Forbes, K., Hanks, G. W., Ferro, C. J., & Chambers, E. J. (2011). A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project. Palliative medicine, 25(5), 525–552. https://doi.org/10.1177/0269216311406313

  57. Vacha, M. E., Huang, W., & Mando-Vandrick, J. (2015). The role of subcutaneous ketorolac for pain management. Hospital pharmacy, 50(2), 108–112. https://doi.org/10.1310/hpj5002-108

  58. Fleming, K., & Donnelly, R. F. (2019). Physical Compatibility and Chemical Stability of Injectable and Oral Ranitidine Solutions. Hospital pharmacy, 54(1), 32–36. https://doi.org/10.1177/0018578718763085

  59. Dahan, A., Yassen, A., Romberg, R., Sarton, E., Teppema, L., Olofsen, E., & Danhof, M. (2006). Buprenorphine induces ceiling in respiratory depression but not in analgesia. British journal of anaesthesia, 96(5), 627–632. https://doi.org/10.1093/bja/ael051

  60. Connock, M., Juarez-Garcia, A., Jowett, S., Frew, E., Liu, Z., Taylor, R. J., Fry-Smith, A., Day, E., Lintzeris, N., Roberts, T., Burls, A., & Taylor, R. S. (2007). Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health technology assessment (Winchester, England), 11(9), 1–iv. https://doi.org/10.3310/hta11090

  61. Alford, D. P., Compton, P., & Samet, J. H. (2006). Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Annals of internal medicine, 144(2), 127–134. https://doi.org/10.7326/0003-4819-144-2-200601170-00010

  62. Reddy, A., Vidal, M., Stephen, S., Baumgartner, K., Dost, S., Nguyen, A., Heung, Y., Kwan, S., Wong, A., Pangemanan, I., Azhar, A., Tayjasanant, S., Rodriguez, E., Waletich, J., Lim, K. H., Wu, J., Liu, D., Williams, J., Yennurajalingam, S., & Bruera, E. (2017). The Conversion Ratio From Intravenous Hydromorphone to Oral Opioids in Cancer Patients. Journal of pain and symptom management, 54(3), 280–288. https://doi.org/10.1016/j.jpainsymman.2017.07.001

  63. Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults. (2022). National Institute for Health and Care Excellence (NICE).

  64. Rosenblum, A., Cruciani, R. A., Strain, E. C., Cleland, C. M., Joseph, H., Magura, S., Marsch, L. A., McNicholas, L. F., Savage, S. R., Sundaram, A., & Portenoy, R. K. (2012). Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol. Journal of opioid management, 8(6), 369–382. https://doi.org/10.5055/jom.2012.0137

  65. Mercadante, S., Porzio, G., Fulfaro, F., Aielli, F., Verna, L., Ficorella, C., Casuccio, A., Riina, S., Intravaia, G., & Mangione, S. (2007). Switching from transdermal drugs: an observational “N of 1” study of fentanyl and buprenorphine. Journal of pain and symptom management, 34(5), 532–538. https://doi.org/10.1016/j.jpainsymman.2007.01.006

  66. Likar R. (2006). Transdermal buprenorphine in the management of persistent pain – safety aspects. Therapeutics and clinical risk management, 2(1), 115–125.

  67. Hale, M., Garofoli, M., & Raffa, R. B. (2021). Benefit-Risk Analysis of Buprenorphine for Pain Management. Journal of pain research, 14, 1359–1369. https://doi.org/10.2147/JPR.S305146

  68. Sittl, R., Likar, R., & Nautrup, B. P. (2005). Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. Clinical therapeutics, 27(2), 225–237. https://doi.org/10.1016/j.clinthera.2005.02.012

  69. Bullingham, R. E., O’Sullivan, G., McQuay, H. J., Poppleton, P., Rolfe, M., Weir, L., & Moore, R. A. (1984). Mandatory sublingual buprenorphine for postoperative pain. Anaesthesia, 39(4), 329–334. https://doi.org/10.1111/j.1365-2044.1984.tb07272.x

  70. Soltani, G., Khorsand, M., Shamloo, A. S., Jarahi, L., & Zirak, N. (2015). Comparison of Intravenous Morphine with Sublingual Buprenorphine in Management of Postoperative Pain after Closed Reduction Orthopedic Surgery. The archives of bone and joint surgery, 3(4), 280–285.

  71. Drover D. R. (2004). Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clinical pharmacokinetics, 43(4), 227–238. https://doi.org/10.2165/00003088-200443040-00002

  72. Cherny N. (2011). Is oral methadone better than placebo or other oral/transdermal opioids in the management of pain?. Palliative medicine, 25(5), 488–493. https://doi.org/10.1177/0269216310397687

  73. James, I. G., O’Brien, C. M., & McDonald, C. J. (2010). A randomized, double-blind, double-dummy comparison of the efficacy and tolerability of low-dose transdermal buprenorphine (BuTrans seven-day patches) with buprenorphine sublingual tablets (Temgesic) in patients with osteoarthritis pain. Journal of pain and symptom management, 40(2), 266–278. https://doi.org/10.1016/j.jpainsymman.2010.01.013

  74. Mercadante, S., Casuccio, A., Tirelli, W., & Giarratano, A. (2009). Equipotent doses to switch from high doses of opioids to transdermal buprenorphine. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 17(6), 715–718. https://doi.org/10.1007/s00520-008-0546-6

  75. Choudhury, K., Dasgupta, P., Paul, N., Choudhury, K. B., Roy, B., & Maity, S. (2018). A Comparative Study of Transdermal Buprenorphine and Oral Morphine in the Treatment of Chronic Pain of Malignant Origin. Indian journal of palliative care, 24(4), 500–504. https://doi.org/10.4103/IJPC.IJPC_83_18

  76. Vermeire, A., & Remon, J. P. (1999). Stability and compatibility of morphine. International journal of pharmaceutics, 187(1), 17–51. https://doi.org/10.1016/s0378-5173(99)00181-7

  77. Elkader, A., & Sproule, B. (2005). Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clinical pharmacokinetics, 44(7), 661–680. https://doi.org/10.2165/00003088-200544070-00001

  78. Darwish, M., Kirby, M., Robertson, P., Jr, Hellriegel, E., & Jiang, J. G. (2006). Comparison of equivalent doses of fentanyl buccal tablets and arteriovenous differences in fentanyl pharmacokinetics. Clinical pharmacokinetics, 45(8), 843–850. https://doi.org/10.2165/00003088-200645080-00006

  79. Schneider, J. J., Good, P., & Ravenscroft, P. J. (2006). Effect of tubing on loss of clonazepam administered by continuous subcutaneous infusion. Journal of pain and symptom management, 31(6), 563–567. https://doi.org/10.1016/j.jpainsymman.2005.09.008

  80. Watson, D. G., Lin, M., Morton, A., Cable, C. G., & McArthur, D. A. (2005). Compatibility and stability of dexamethasone sodium phosphate and ketamine hydrochloride subcutaneous infusions in polypropylene syringes. Journal of pain and symptom management, 30(1), 80–86. https://doi.org/10.1016/j.jpainsymman.2005.01.018

  81. Caraceni, A., Pigni, A., & Brunelli, C. (2011). Is oral morphine still the first choice opioid for moderate to severe cancer pain? A systematic review within the European Palliative Care Research Collaborative guidelines project. Palliative medicine, 25(5), 402–409. https://doi.org/10.1177/0269216310392102

  82. King, S., Forbes, K., Hanks, G. W., Ferro, C. J., & Chambers, E. J. (2011). A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project. Palliative medicine, 25(5), 525–552. https://doi.org/10.1177/0269216311406313

  83. Dickman, A., Bickerstaff, M., Jackson, R., Schneider, J., Mason, S., & Ellershaw, J. (2017). Identification of drug combinations administered by continuous subcutaneous infusion that require analysis for compatibility and stability. BMC palliative care, 16(1), 22. https://doi.org/10.1186/s12904-017-0195-y

  84. Caraceni, A., Hanks, G., Kaasa, S., Bennett, M. I., Brunelli, C., Cherny, N., Dale, O., De Conno, F., Fallon, M., Hanna, M., Haugen, D. F., Juhl, G., King, S., Klepstad, P., Laugsand, E. A., Maltoni, M., Mercadante, S., Nabal, M., Pigni, A., Radbruch, L., … European Association for Palliative Care (EAPC) (2012). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. The Lancet. Oncology, 13(2), e58–e68. https://doi.org/10.1016/S1470-2045(12)70040-2

  85. Vallner, J. J., Stewart, J. T., Kotzan, J. A., Kirsten, E. B., & Honigberg, I. L. (1981). Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects. Journal of clinical pharmacology, 21(4), 152–156. https://doi.org/10.1002/j.1552-4604.1981.tb05693.x

  86. King, S., Forbes, K., Hanks, G. W., Ferro, C. J., & Chambers, E. J. (2011). A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project. Palliative medicine, 25(5), 525–552. https://doi.org/10.1177/0269216311406313

  87. Babul, N., & Darke, A. C. (1992). Putative role of hydromorphone metabolites in myoclonus. Pain, 51(2), 260–261. https://doi.org/10.1016/0304-3959(92)90270-L

  88. Darwish, M., Kirby, M., Robertson, P., Jr, Tracewell, W., & Jiang, J. G. (2006). Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers. Clinical therapeutics, 28(5), 707–714. https://doi.org/10.1016/j.clinthera.2006.05.015

  89. Mercadante, S., & Caraceni, A. (2011). Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review. Palliative medicine, 25(5), 504–515. https://doi.org/10.1177/0269216311406577

  90. Inoue, S., Saito, Y., Tsuneto, S., Aruga, E., Ogata, T., & Uemori, M. (2018). A double-blind, randomized comparative study to investigate the morphine to hydromorphone conversion ratio in Japanese cancer patients. Japanese journal of clinical oncology, 48(5), 442–449. https://doi.org/10.1093/jjco/hyy046

  91. Wittwer, E., & Kern, S. E. (2006). Role of morphine’s metabolites in analgesia: concepts and controversies. The AAPS journal, 8(2), E348–E352. https://doi.org/10.1007/BF02854905

  92. Reddy, A., Vidal, M., Stephen, S., Baumgartner, K., Dost, S., Nguyen, A., Heung, Y., Kwan, S., Wong, A., Pangemanan, I., Azhar, A., Tayjasanant, S., Rodriguez, E., Waletich, J., Lim, K. H., Wu, J., Liu, D., Williams, J., Yennurajalingam, S., & Bruera, E. (2017). The Conversion Ratio From Intravenous Hydromorphone to Oral Opioids in Cancer Patients. Journal of pain and symptom management, 54(3), 280–288. https://doi.org/10.1016/j.jpainsymman.2017.07.001

  93. Bruera, E., Sloan, P., Mount, B., Scott, J., & Suarez-Almazor, M. (1996). A randomized, double-blind, double-dummy, crossover trial comparing the safety and efficacy of oral sustained-release hydromorphone with immediate-release hydromorphone in patients with cancer pain. Canadian Palliative Care Clinical Trials Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14(5), 1713–1717. https://doi.org/10.1200/JCO.1996.14.5.1713

  94. Caraceni, A., Hanks, G., Kaasa, S., Bennett, M. I., Brunelli, C., Cherny, N., Dale, O., De Conno, F., Fallon, M., Hanna, M., Haugen, D. F., Juhl, G., King, S., Klepstad, P., Laugsand, E. A., Maltoni, M., Mercadante, S., Nabal, M., Pigni, A., Radbruch, L., … European Association for Palliative Care (EAPC) (2012). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. The Lancet. Oncology, 13(2), e58–e68. https://doi.org/10.1016/S1470-2045(12)70040-2

  95. Davis, M. P., & Walsh, D. (2001). Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 9(2), 73–83. https://doi.org/10.1007/s005200000180

  96. Baumrucker, S. J., Jbara, M., & Rogers, R. M. (2016). A new mathematical approach to methadone conversion. Journal of pharmacology & pharmacotherapeutics, 7(2), 93–95. https://doi.org/10.4103/0976-500X.184773

  97. Ferrari, A., Coccia, C. P., Bertolini, A., & Sternieri, E. (2004). Methadone–metabolism, pharmacokinetics and interactions. Pharmacological research, 50(6), 551–559. https://doi.org/10.1016/j.phrs.2004.05.002

  98. Fainsinger, R., Schoeller, T., & Bruera, E. (1993). Methadone in the management of cancer pain: a review. Pain, 52(2), 137–147. https://doi.org/10.1016/0304-3959(93)90125-9

  99. Verebely, K., & Kutt, H. (1975). Methadone plasma levels in maintenance patients: the effect of dose omission. Research communications in chemical pathology and pharmacology, 11(3), 373–386.

  100. Jiang, H., Hillhouse, M., Du, J., Pan, S., Alfonso, A., Wang, J., Zhou, Z., Yuan, W., Ling, W., & Zhao, M. (2016). Dose, Plasma Level, and Treatment Outcome Among Methadone Patients in Shanghai, China. Neuroscience bulletin, 32(6), 538–544. https://doi.org/10.1007/s12264-016-0059-0

  101. Bosilkovska, M., Walder, B., Besson, M., Daali, Y., & Desmeules, J. (2012). Analgesics in patients with hepatic impairment: pharmacology and clinical implications. Drugs, 72(12), 1645–1669. https://doi.org/10.2165/11635500-000000000-00000

  102. Säwe, J., Hansen, J., Ginman, C., Hartvig, P., Jakobsson, P. A., Nilsson, M. I., Rane, A., & Anggård, E. (1981). Patient-controlled dose regimen of methadone for chronic cancer pain. British medical journal (Clinical research ed.), 282(6266), 771–773. https://doi.org/10.1136/bmj.282.6266.771

  103. Caraceni, A., Hanks, G., Kaasa, S., Bennett, M. I., Brunelli, C., Cherny, N., Dale, O., De Conno, F., Fallon, M., Hanna, M., Haugen, D. F., Juhl, G., King, S., Klepstad, P., Laugsand, E. A., Maltoni, M., Mercadante, S., Nabal, M., Pigni, A., Radbruch, L., … European Association for Palliative Care (EAPC) (2012). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. The Lancet. Oncology, 13(2), e58–e68. https://doi.org/10.1016/S1470-2045(12)70040-2

  104. Benítez-Rosario, M. A., Salinas-Martín, A., Aguirre-Jaime, A., Pérez-Méndez, L., & Feria, M. (2009). Morphine-methadone opioid rotation in cancer patients: analysis of dose ratio predicting factors. Journal of pain and symptom management, 37(6), 1061–1068. https://doi.org/10.1016/j.jpainsymman.2008.05.016

  105. Inoue, S., Saito, Y., Tsuneto, S., Aruga, E., Ogata, T., & Uemori, M. (2018). A double-blind, randomized comparative study to investigate the morphine to hydromorphone conversion ratio in Japanese cancer patients. Japanese journal of clinical oncology, 48(5), 442–449. https://doi.org/10.1093/jjco/hyy046

  106. Ferry, J. J., Horvath, A. M., Bekersky, I., Heath, E. C., Ryan, C. F., & Colburn, W. A. (1988). Relative and absolute bioavailability of prednisone and prednisolone after separate oral and intravenous doses. Journal of clinical pharmacology, 28(1), 81–87. https://doi.org/10.1002/j.1552-4604.1988.tb03105.x

  107. Mercadante, S., Porzio, G., Ferrera, P., Fulfaro, F., Aielli, F., Verna, L., Villari, P., Ficorella, C., Gebbia, V., Riina, S., Casuccio, A., & Mangione, S. (2008). Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. European journal of pain (London, England), 12(8), 1040–1046. https://doi.org/10.1016/j.ejpain.2008.01.013

  108. Mercadante, S., Casuccio, A., & Calderone, L. (1999). Rapid switching from morphine to methadone in cancer patients with poor response to morphine. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17(10), 3307–3312. https://doi.org/10.1200/JCO.1999.17.10.3307

  109. Porta-Sales, J., Garzón-Rodríguez, C., Villavicencio-Chávez, C., Llorens-Torromé, S., & González-Barboteo, J. (2016). Efficacy and Safety of Methadone as a Second-Line Opioid for Cancer Pain in an Outpatient Clinic: A Prospective Open-Label Study. The oncologist, 21(8), 981–987. https://doi.org/10.1634/theoncologist.2015-0503

  110. Morita, T., Takigawa, C., Onishi, H., Tajima, T., Tani, K., Matsubara, T., Miyoshi, I., Ikenaga, M., Akechi, T., Uchitomi, Y., & Japan Pain, Rehabilitation, Palliative Medicine, and Psycho-Oncology (PRPP) Study Group (2005). Opioid rotation from morphine to fentanyl in delirious cancer patients: an open-label trial. Journal of pain and symptom management, 30(1), 96–103. https://doi.org/10.1016/j.jpainsymman.2004.12.010

  111. Centeno, C., & Vara, F. (2005). Intermittent subcutaneous methadone administration in the management of cancer pain. Journal of pain & palliative care pharmacotherapy, 19(2), 7–12.

  112. Mathew, P., & Storey, P. (1999). Subcutaneous methadone in terminally ill patients: manageable local toxicity. Journal of pain and symptom management, 18(1), 49–52. https://doi.org/10.1016/s0885-3924(99)00020-2

  113. Fallon, M. T., & Laird, B. J. (2011). A systematic review of combination step III opioid therapy in cancer pain: an EPCRC opioid guideline project. Palliative medicine, 25(5), 597–603. https://doi.org/10.1177/0269216310392101

  114. Zimmermann, C., Seccareccia, D., Booth, C. M., & Cottrell, W. (2005). Rotation to methadone after opioid dose escalation: How should individualization of dosing occur?. Journal of pain & palliative care pharmacotherapy, 19(2), 25–31.

  115. Hagen, N. A., & Wasylenko, E. (1999). Methadone: outpatient titration and monitoring strategies in cancer patients. Journal of pain and symptom management, 18(5), 369–375. https://doi.org/10.1016/s0885-3924(99)00083-4

  116. Lukin, B., Greenslade, J., Kearney, A. M., Douglas, C., Howell, T., Barras, M., & Good, P. (2020). Conversion of other opioids to methadone: a retrospective comparison of two methods. BMJ supportive & palliative care, 10(2), 201–204. https://doi.org/10.1136/bmjspcare-2018-001645

  117. Moksnes, K., Kaasa, S., Paulsen, Ø., Rosland, J. H., Spigset, O., & Dale, O. (2012). Serum concentrations of opioids when comparing two switching strategies to methadone for cancer pain. European journal of clinical pharmacology, 68(8), 1147–1156. https://doi.org/10.1007/s00228-012-1228-3

  118. Stielow, M., Witczyńska, A., Kubryń, N., Fijałkowski, Ł., Nowaczyk, J., & Nowaczyk, A. (2023). The Bioavailability of Drugs-The Current State of Knowledge. Molecules (Basel, Switzerland), 28(24), 8038. https://doi.org/10.3390/molecules28248038

  119. Blackburn D 2005) Methadone: the analgesic. European Journal of Palliative Care. 12: 188-191.

  120. Rowley, D., McLean, S., O’Gorman, A., Ryan, K., & McQuillan, R. (2011). Review of cancer pain management in patients receiving maintenance methadone therapy. The American journal of hospice & palliative care, 28(3), 183–187. https://doi.org/10.1177/1049909110380897

  121. Sugiyama, Y., Sakamoto, N., Ohsawa, M., Onizuka, M., Ishida, K., Murata, Y., Iio, A., Sugano, K., Maeno, K., Takeyama, H., Akechi, T., & Kimura, K. (2016). A Retrospective Study on the Effectiveness of Switching to Oral Methadone for Relieving Severe Cancer-Related Neuropathic Pain and Limiting Adjuvant Analgesic Use in Japan. Journal of palliative medicine, 19(10), 1051–1059. https://doi.org/10.1089/jpm.2015.0303

  122. Fisher, K., Stiles, C., & Hagen, N. A. (2004). Characterization of the early pharmacodynamic profile of oral methadone for cancer-related breakthrough pain: a pilot study. Journal of pain and symptom management, 28(6), 619–625. https://doi.org/10.1016/j.jpainsymman.2004.03.003

  123. Heiskanen, T., & Kalso, E. (1997). Controlled-release oxycodone and morphine in cancer related pain. Pain, 73(1), 37–45. https://doi.org/10.1016/s0304-3959(97)00072-9

  124. Bruera, E., Belzile, M., Pituskin, E., Fainsinger, R., Darke, A., Harsanyi, Z., Babul, N., & Ford, I. (1998). Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16(10), 3222–3229. https://doi.org/10.1200/JCO.1998.16.10.3222

  125. Curtis, G. B., Johnson, G. H., Clark, P., Taylor, R., Brown, J., O’Callaghan, R., Shi, M., & Lacouture, P. G. (1999). Relative potency of controlled-release oxycodone and controlled-release morphine in a postoperative pain model. European journal of clinical pharmacology, 55(6), 425–429. https://doi.org/10.1007/s002280050651

  126. Lauretti, G. R., Oliveira, G. M., & Pereira, N. L. (2003). Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients. British journal of cancer, 89(11), 2027–2030. https://doi.org/10.1038/sj.bjc.6601365

  127. Kalso, E., Pöyhiä, R., Onnela, P., Linko, K., Tigerstedt, I., & Tammisto, T. (1991). Intravenous morphine and oxycodone for pain after abdominal surgery. Acta anaesthesiologica Scandinavica, 35(7), 642–646. https://doi.org/10.1111/j.1399-6576.1991.tb03364.x

  128. Silvasti, M., Rosenberg, P., Seppälä, T., Svartling, N., & Pitkänen, M. (1998). Comparison of analgesic efficacy of oxycodone and morphine in postoperative intravenous patient-controlled analgesia. Acta anaesthesiologica Scandinavica, 42(5), 576–580. https://doi.org/10.1111/j.1399-6576.1998.tb05169.x

  129. Nicholson, A. B., Watson, G. R., Derry, S., & Wiffen, P. J. (2017). Methadone for cancer pain. The Cochrane database of systematic reviews, 2(2), CD003971. https://doi.org/10.1002/14651858.CD003971.pub4

  130. Huddart, R., Clarke, M., Altman, R. B., & Klein, T. E. (2018). PharmGKB summary: oxycodone pathway, pharmacokinetics. Pharmacogenetics and genomics, 28(10), 230–237. https://doi.org/10.1097/FPC.0000000000000351

  131. Charles, B., Hardy, J., Anderson, H., Tapuni, A., George, R., & Norris, R. (2014). Should the dosage of controlled-release oxycodone in advanced cancer be modified on the basis of patient characteristics?. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 22(2), 325–330. https://doi.org/10.1007/s00520-013-1973-6

  132. Leow, K. P., Smith, M. T., Williams, B., & Cramond, T. (1992). Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. Clinical pharmacology and therapeutics, 52(5), 487–495. https://doi.org/10.1038/clpt.1992.176

  133. Dahan, A., Yassen, A., Romberg, R., Sarton, E., Teppema, L., Olofsen, E., & Danhof, M. (2006). Buprenorphine induces ceiling in respiratory depression but not in analgesia. British journal of anaesthesia, 96(5), 627–632. https://doi.org/10.1093/bja/ael051

  134. Kleine-Brueggeney, M., Musshoff, F., Stuber, F., & Stamer, U. M. (2010). Pharmacogenetics in palliative care. Forensic science international, 203(1-3), 63–70. https://doi.org/10.1016/j.forsciint.2010.07.003

  135. Westdorp, H., Kuip, E. J. M., van Oort, I. M., Kramers, C., Gerritsen, W. R., & Vissers, K. C. P. (2018). Difficulties in Pain Management Using Oxycodone and Fentanyl in Enzalutamide-Treated Patients With Advanced Prostate Cancer. Journal of pain and symptom management, 55(4), e6–e8. https://doi.org/10.1016/j.jpainsymman.2017.11.016

  136. Baker, J., Dickman, A., Mason, S., Bickerstaff, M., Jackson, R., McArdle, A., Lawrence, I., Stephenson, F., Paton, N., Kirk, J., Waters, B., & Ellershaw, J. (2020). An evaluation of continuous subcutaneous infusions across seven NHS acute hospitals: is there potential for 48-hour infusions?. BMC palliative care, 19(1), 99. https://doi.org/10.1186/s12904-020-00611-3

  137. Cheung, K. C., Bouvy, M. L., & De Smet, P. A. (2009). Medication errors: the importance of safe dispensing. British journal of clinical pharmacology, 67(6), 676–680. https://doi.org/10.1111/j.1365-2125.2009.03428.x

  138. Kornick, C. A., Santiago-Palma, J., Khojainova, N., Primavera, L. H., Payne, R., & Manfredi, P. L. (2001). A safe and effective method for converting cancer patients from intravenous to transdermal fentanyl. Cancer, 92(12), 3056–3061. https://doi.org/10.1002/1097-0142(20011215)92:12<3056::aid-cncr10166>3.0.co;2-h

  139. Carlson C. L. (2016). Effectiveness of the World Health Organization cancer pain relief guidelines: an integrative review. Journal of pain research, 9, 515–534. https://doi.org/10.2147/JPR.S97759

  140. Treillet, E., Laurent, S., & Hadjiat, Y. (2018). Practical management of opioid rotation and equianalgesia. Journal of pain research, 11, 2587–2601. https://doi.org/10.2147/JPR.S170269

  141. Nelson, K. A., Glare, P. A., Walsh, D., & Groh, E. S. (1997). A prospective, within-patient, crossover study of continuous intravenous and subcutaneous morphine for chronic cancer pain. Journal of pain and symptom management, 13(5), 262–267. https://doi.org/10.1016/s0885-3924(96)00329-6

  142. Spoorenberg, S. M., Deneer, V. H., Grutters, J. C., Pulles, A. E., Voorn, G. P., Rijkers, G. T., Bos, W. J., & van de Garde, E. M. (2014). Pharmacokinetics of oral vs. intravenous dexamethasone in patients hospitalized with community-acquired pneumonia. British journal of clinical pharmacology, 78(1), 78–83. https://doi.org/10.1111/bcp.12295

  143. Al-Tannak, N. F., Cable, C. G., McArthur, D. A., & Watson, D. G. (2012). A stability indicating assay for a combination of morphine sulphate with levomepromazine hydrochloride used in palliative care. Journal of clinical pharmacy and therapeutics, 37(1), 71–73. https://doi.org/10.1111/j.1365-2710.2011.01252.x

  144. Donnelly R. F. (2009). Physical compatibility and chemical stability of ketamine-morphine mixtures in polypropylene syringes. The Canadian journal of hospital pharmacy, 62(1), 28–33. https://doi.org/10.4212/cjhp.v62i1.114

  145. Storm, M. C., Broyles, J. E., Herrera, O. R., & Helms, R. A. (2022). Stability of 4 Intravenous Drug Formulations in Prefilled Syringes Stored Frozen for Up to 60 Days. Hospital pharmacy, 57(1), 61–68. https://doi.org/10.1177/0018578720973880

  146. Barcia, E., Reyes, R., Luz Azuara, M., Sánchez, Y., & Negro, S. (2003). Compatibility of haloperidol and hyoscine-N-butyl bromide in mixtures for subcutaneous infusion to cancer patients in palliative care. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 11(2), 107–113. https://doi.org/10.1007/s00520-002-0415-7

  147. Fielding, H., Kyaterekera, N., Skellern, G. G., Tettey, J. N., McDade, J. R., Msuya, Z., Watson, D. G., & Urie, J. (2000). The compatibility and stability of octreotide acetate in the presence of diamorphine hydrochloride in polypropylene syringes. Palliative medicine, 14(3), 205–207. https://doi.org/10.1191/026921600666997498

  148. Grassby, P. F., & Hutchings, L. (1997). Drug combinations in syringe drivers: the compatibility and stability of diamorphine with cyclizine and haloperidol. Palliative medicine, 11(3), 217–224. https://doi.org/10.1177/026921639701100306

  149. Simpson, R. J., Power, K. G., Wallace, L. A., Butcher, M. H., Swanson, V., & Simpson, E. C. (1990). Controlled comparison of the characteristics of long-term benzodiazepine users in general practice. The British journal of general practice : the journal of the Royal College of General Practitioners, 40(330), 22–26.

  150. Beigmohammadi, M. T., Hanifeh, M., Rouini, M. R., Sheikholeslami, B., & Mojtahedzadeh, M. (2013). Pharmacokinetics Alterations of Midazolam Infusion versus Bolus Administration in Mechanically Ventilated Critically Ill Patients. Iranian journal of pharmaceutical research : IJPR, 12(2), 483–488.

  151. Lau, M. H., Hackman, C., & Morgan, D. J. (1998). Compatibility of ketamine and morphine injections. Pain, 75(2-3), 389–390. https://doi.org/10.1016/s0304-3959(97)00176-0

  152. Negro, S., Azuara, M. L., Sánchez, Y., Reyes, R., & Barcia, E. (2002). Physical compatibility and in vivo evaluation of drug mixtures for subcutaneous infusion to cancer patients in palliative care. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 10(1), 65–70. https://doi.org/10.1007/s005200100303

  153. Mucci-LoRusso, P., Berman, B. S., Silberstein, P. T., Citron, M. L., Bressler, L., Weinstein, S. M., Kaiko, R. F., Buckley, B. J., & Reder, R. F. (1998). Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study. European journal of pain (London, England), 2(3), 239–249. https://doi.org/10.1016/s1090-3801(98)90020-9

  154. Dickman, A., Bickerstaff, M., Jackson, R., Schneider, J., Mason, S., & Ellershaw, J. (2017). Identification of drug combinations administered by continuous subcutaneous infusion that require analysis for compatibility and stability. BMC palliative care, 16(1), 22. https://doi.org/10.1186/s12904-017-0195-y

  155. Liu, S., Liu, X., Chen, S., Xiao, Y., & Zhuang, W. (2017). Oral versus intravenous methylprednisolone for the treatment of multiple sclerosis relapses: A meta-analysis of randomized controlled trials. PloS one, 12(11), e0188644. https://doi.org/10.1371/journal.pone.0188644

  156. Storey, P., Hill, H. H., Jr, St Louis, R. H., & Tarver, E. E. (1990). Subcutaneous infusions for control of cancer symptoms. Journal of pain and symptom management, 5(1), 33–41. https://doi.org/10.1016/s0885-3924(05)80007-7

  157. Bruera, E., Palmer, J. L., Bosnjak, S., Rico, M. A., Moyano, J., Sweeney, C., Strasser, F., Willey, J., Bertolino, M., Mathias, C., Spruyt, O., & Fisch, M. J. (2004). Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22(1), 185–192. https://doi.org/10.1200/JCO.2004.03.172

  158. Malinoff, H. L., Barkin, R. L., & Wilson, G. (2005). Sublingual buprenorphine is effective in the treatment of chronic pain syndrome. American journal of therapeutics, 12(5), 379–384. https://doi.org/10.1097/01.mjt.0000160935.62883.ff

  159. McLean, S., & Twomey, F. (2015). Methods of Rotation From Another Strong Opioid to Methadone for the Management of Cancer Pain: A Systematic Review of the Available Evidence. Journal of pain and symptom management, 50(2), 248–59.e1. https://doi.org/10.1016/j.jpainsymman.2015.02.029

  160. Cuschieri, R. J., Morran, C. G., & McArdle, C. S. (1984). Comparison of morphine and sublingual buprenorphine following abdominal surgery. British journal of anaesthesia, 56(8), 855–859. https://doi.org/10.1093/bja/56.8.855

  161. Treillet, E., Laurent, S., & Hadjiat, Y. (2018). Practical management of opioid rotation and equianalgesia. Journal of pain research, 11, 2587–2601. https://doi.org/10.2147/JPR.S170269

  162. Biancofiore G. (2006). Oxycodone controlled release in cancer pain management. Therapeutics and clinical risk management, 2(3), 229–234. https://doi.org/10.2147/tcrm.2006.2.3.229

  163. Jäppinen, A., Kokki, H., Naaranlahti, T. J., & Rasi, A. S. (1999). Stability of buprenorphine, haloperidol and glycopyrrolate mixture in a 0.9% sodium chloride solution. Pharmacy world & science : PWS, 21(6), 272–274. https://doi.org/10.1023/a:1008771621812¥

  164.  Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults. (2022). National Institute for Health and Care Excellence (NICE).

  165. Nadeau, S. E., Wu, J. K., & Lawhern, R. A. (2021). Opioids and Chronic Pain: An Analytic Review of the Clinical Evidence. Frontiers in pain research (Lausanne, Switzerland), 2, 721357. https://doi.org/10.3389/fpain.2021.721357

  166. Reynolds, L., Rauck, R., Webster, L., DuPen, S., Heinze, E., Portenoy, R., Katz, N., Charapata, S., Wallace, M., & Fisher, D. M. (2004). Relative analgesic potency of fentanyl and sufentanil during intermediate-term infusions in patients after long-term opioid treatment for chronic pain. Pain, 110(1-2), 182–188. https://doi.org/10.1016/j.pain.2004.03.024

  167. Beaver, W. T., & Feise, G. A. (1978). A comparison of the analgesic effect of intramuscular nalbuphine and morphine in patients with postoperative pain. The Journal of pharmacology and experimental therapeutics, 204(2), 487–496.

  168. Kaiko, R. F., Wallenstein, S. L., Rogers, A., Grabinski, P., & Houde, R. W. (1981). Relative analgesic potency of intramuscular heroin and morphine in cancer patients with postoperative pain and chronic pain due to cancer. NIDA research monograph, 34, 213–219.

  169. White, C., Hardy, J., Boyd, A., & Hall, A. (2008). Subcutaneous sufentanil for palliative care patients in a hospital setting. Palliative medicine, 22(1), 89–90. https://doi.org/10.1177/0269216307085177

  170. Davis M. P. (2004). Acute pain in advanced cancer: an opioid dosing strategy and illustration. The American journal of hospice & palliative care, 21(1), 47–50. https://doi.org/10.1177/104990910402100111

  171. Dickman, Andrew, Drugs in Palliative Care, 3 edn (Oxford, 2023; online edn, Oxford Academic, 1 Feb. 2023) https://www.pharmaceuticalpress.com/product/palliativecareformularypcf8/

  172. Davis, M. P., Weissman, D. E., & Arnold, R. M. (2004). Opioid dose titration for severe cancer pain: a systematic evidence-based review. Journal of palliative medicine, 7(3), 462–468. https://doi.org/10.1089/1096621041349581

  173. Dundee, J. W., Loan, W. B., & Clarke, R. S. (1966). Studies of drugs given before anaesthesia. XI. Diamorphine (heroin) and morphine. British journal of anaesthesia, 38(8), 610–619. https://doi.org/10.1093/bja/38.8.610

  174. Kissin, I., Bright, C. A., & Bradley, E. L., Jr (2000). Acute tolerance to continuously infused alfentanil: the role of cholecystokinin and N-methyl-D-aspartate-nitric oxide systems. Anesthesia and analgesia, 91(1), 110–116. https://doi.org/10.1097/00000539-200007000-00021

  175. Davis, M. P., Weissman, D. E., & Arnold, R. M. (2004). Opioid dose titration for severe cancer pain: a systematic evidence-based review. Journal of palliative medicine, 7(3), 462–468. https://doi.org/10.1089/1096621041349581

  176. Charlesworth, S. (Ed.). (2022). Palliative Care Formulary (8th ed.). Pharmaceutical Press, https://www.pharmaceuticalpress.com/product/palliativecareformularypcf8/

  177. Willens, J. S., & Myslinski, N. R. (1993). Pharmacodynamics, pharmacokinetics, and clinical uses of fentanyl, sufentanil, and alfentanil. Heart & lung : the journal of critical care, 22(3), 239–251.

  178. Kwon, Y. S., Jang, J. S., Lee, N. R., Kim, S. S., Kim, Y. K., Hwang, B. M., Kang, S. S., Son, H. J., & Lim, S. Y. (2016). A Comparison of Oxycodone and Alfentanil in Intravenous Patient-Controlled Analgesia with a Time-Scheduled Decremental Infusion after Laparoscopic Cholecystectomy. Pain research & management, 2016, 7868152. https://doi.org/10.1155/2016/7868152

  179. Cran, A., Dorman, S., & Kirkham, S. (2017). Opioid rotation to alfentanil: comparative evaluation of conversion ratios. BMJ supportive & palliative care, 7(3), 265–266. https://doi.org/10.1136/bmjspcare-2017-001349

  180. White, C., Hardy, J., Boyd, A., & Hall, A. (2008). Subcutaneous sufentanil for palliative care patients in a hospital setting. Palliative medicine, 22(1), 89–90. https://doi.org/10.1177/0269216307085177

  181. Kaiko, R. F., Wallenstein, S. L., Rogers, A., Grabinski, P., & Houde, R. W. (1981). Relative analgesic potency of intramuscular heroin and morphine in cancer patients with postoperative pain and chronic pain due to cancer. NIDA research monograph, 34, 213–219.

  182. Alizadeh, S., Mahmoudi, G. A., Solhi, H., Sadeghi-Sedeh, B., Behzadi, R., & Kazemifar, A. M. (2015). Post-operative Analgesia in Opioid Dependent Patients: Comparison of Intravenous Morphine and Sublingual Buprenorphine. Addiction & health, 7(1-2), 60–65.

  183. Others :
    https://www.benzoinfo.com
    https://www.benzo.org.uk/index.htm
    https://www.sciencedirect.com/book/9780323847025
    https://www.pharmaceuticalpress.com/products/palliative-care-formulary/
    https://cbip.be/fr/
    https://www.fda.gov
    Adult Drug Information Handbook, 32 th edition, American Pharmacists Association (APhA), Wolters Kluwer Edition.

This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.